In case of encouraging results in mechanistic studies, observational studies, involving patients with obesity and/or T2DM and concomitant HCC on GLP-1RAs and/or PPAR modulators, may be the rational next step to evaluate the association between the specific anti-diabetic medications with HCC. This evidence concerns the gene PPARA and hepatocellular carcinoma.